IL311101A - RNA editing through recruitment of SPLICEOSOME components - Google Patents

RNA editing through recruitment of SPLICEOSOME components

Info

Publication number
IL311101A
IL311101A IL311101A IL31110124A IL311101A IL 311101 A IL311101 A IL 311101A IL 311101 A IL311101 A IL 311101A IL 31110124 A IL31110124 A IL 31110124A IL 311101 A IL311101 A IL 311101A
Authority
IL
Israel
Prior art keywords
rna editing
editing via
via recruitment
spliceosome components
spliceosome
Prior art date
Application number
IL311101A
Other languages
English (en)
Hebrew (he)
Inventor
David A Nelles
Original Assignee
Tacit Therapeutics Inc
David A Nelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tacit Therapeutics Inc, David A Nelles filed Critical Tacit Therapeutics Inc
Publication of IL311101A publication Critical patent/IL311101A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL311101A 2021-09-03 2022-09-02 RNA editing through recruitment of SPLICEOSOME components IL311101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240428P 2021-09-03 2021-09-03
US202263345660P 2022-05-25 2022-05-25
PCT/US2022/042486 WO2023034582A1 (en) 2021-09-03 2022-09-02 Rna editing via recruitment of spliceosome components

Publications (1)

Publication Number Publication Date
IL311101A true IL311101A (en) 2024-04-01

Family

ID=85412903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311101A IL311101A (en) 2021-09-03 2022-09-02 RNA editing through recruitment of SPLICEOSOME components

Country Status (9)

Country Link
US (2) US12152239B2 (https=)
EP (1) EP4396350A4 (https=)
JP (1) JP2024533163A (https=)
KR (1) KR20240052034A (https=)
AU (1) AU2022337146A1 (https=)
CA (1) CA3230419A1 (https=)
IL (1) IL311101A (https=)
MX (1) MX2024002647A (https=)
WO (1) WO2023034582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022220968A1 (en) * 2021-04-15 2022-10-20 U1 Bio, Inc. High efficiency trans-splicing for replacement of targeted rna sequences in human cells
AU2022337146A1 (en) 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components
EP4522758A4 (en) 2022-05-13 2026-05-06 Ascidian Therapeutics Inc Abca4 trans-splicing molecules
WO2025085691A1 (en) 2023-10-18 2025-04-24 Tacit Therapeutics, Inc. Trans-splicing nucleic acid molecules and methods of use
WO2025147110A1 (ko) * 2024-01-02 2025-07-10 알지노믹스 주식회사 Mecp2 전사체 특이적 트랜스-스플라이싱 리보자임 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193580A1 (en) 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
IT1283876B1 (it) * 1996-01-12 1998-05-07 Univ Roma Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US20040214263A1 (en) * 2002-03-20 2004-10-28 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing
FR2874384B1 (fr) * 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
EP2151248A1 (en) 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
US9303078B2 (en) 2009-10-08 2016-04-05 Association Institut De Myologie Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
US8802642B2 (en) 2010-04-28 2014-08-12 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting SMN2 catalytic core
IT1400425B1 (it) * 2010-06-08 2013-05-31 Amsterdam Molecular Therapeutics Bv Modified snrnas for use in therapy.
IT1405793B1 (it) * 2010-10-15 2014-01-24 Univ Ferrara Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
GB201219762D0 (en) 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
MX388221B (es) 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
CA3005474A1 (en) 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
CA3005968A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
EP3436590A4 (en) * 2016-04-01 2019-12-04 National University of Singapore TRANSSPLEISSEN OF RNA (TSRNA)
CN110612353A (zh) 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
KR102866133B1 (ko) 2018-04-17 2025-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
KR102918544B1 (ko) 2018-07-12 2026-01-27 로켓 파마슈티컬스, 리미티드 다논병을 치료하기 위한 유전자 요법 벡터
US20220010333A1 (en) 2018-09-06 2022-01-13 The Regents Of The University Of California Rna and dna base editing via engineered adar recruitment
US20210388351A1 (en) 2018-09-28 2021-12-16 The Jackson Laboratory Artificial rna-guided splicing factors
WO2020160486A1 (en) 2019-02-01 2020-08-06 Spark Therapeutics, Inc. Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2
WO2020205604A1 (en) 2019-03-29 2020-10-08 Salk Institute For Biological Studies High-efficiency reconstitution of rna molecules
BR112021020539A2 (pt) 2019-04-17 2022-01-04 Univ Pennsylvania Terminador de hélice tripla para trans-splicing de rna eficiente
CN115023499A (zh) 2019-08-16 2022-09-06 麻省理工学院 使用CRISPR/Cas13的靶向反式剪接
WO2021076656A1 (en) 2019-10-15 2021-04-22 University Of Massachusetts Rna editor-enhanced rna trans-splicing
IL292904A (en) * 2019-11-11 2022-07-01 Salk Inst For Biological Studi Compositions and methods for high-efficiency recombination of rna molecules
CN115777020A (zh) 2020-04-22 2023-03-10 塑造治疗公司 使用snrna组分的组合物和方法
CA3177380A1 (en) 2020-05-26 2021-12-02 Shape Therapeutics Inc. Compositions and methods for modifying target rnas
EP4217010A4 (en) 2020-09-28 2025-01-08 Tacit Therapeutics, Inc. TRANS-SPLICING SYSTEM FOR TISSUE-SPECIFIC REPLACEMENT OF RNA SEQUENCES
AU2022337146A1 (en) 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components

Also Published As

Publication number Publication date
EP4396350A1 (en) 2024-07-10
WO2023034582A1 (en) 2023-03-09
US20240011026A1 (en) 2024-01-11
KR20240052034A (ko) 2024-04-22
US20250051764A1 (en) 2025-02-13
MX2024002647A (es) 2024-05-10
CA3230419A1 (en) 2023-03-09
JP2024533163A (ja) 2024-09-12
AU2022337146A1 (en) 2024-03-14
EP4396350A4 (en) 2026-01-14
US12152239B2 (en) 2024-11-26

Similar Documents

Publication Publication Date Title
IL311101A (en) RNA editing through recruitment of SPLICEOSOME components
GB2612212B (en) Compositions and methods for gene editing
EP4240849A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
IL304263A (en) RNA structure with self-circulation
EP4153604A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
IL286395A (en) Chemically modified oligonucleotides for RNA editing
GB2601618B (en) Methods and compositions for editing nucleotide sequences
GB202011428D0 (en) Antisense oligonucleotides for RNA editing
IL273817A (en) Preparations and methods for editing rna
ZA201704779B (en) Composition and methods for regulated expression of a guide rna/cas endonuclease complex
IL278401A (en) Polynucleotides for editing RNA and a method for using them
EP4396354A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
GB201907733D0 (en) Methods and compositions for multiplex gene editing
IL287293A (en) RNA editing inhibitors and methods of use
EP4100003A4 (en) Improved methods and compositions for cromakalim prodrug therapy
IL320277A (en) Compositions and methods including programmable snRNAs for RNA editing
EP4367239A4 (en) CRISPR-BASED PROGRAMMABLE RNA EDITING
GB202113933D0 (en) Methods for gene editing
SG10201906239RA (en) Compositions and methods for inhibition of rna editing for treatment of cancer
GB202101107D0 (en) Method of genome editing
GB202305894D0 (en) Compositions and methods for RNA synthesis
KR102587121B9 (ko) Rna 분리용 조성물
GB202117455D0 (en) Method of editing nucleic acid
CA232523S (en) Swimwear
CA232518S (en) Swimwear